<?xml version="1.0" encoding="UTF-8"?>
<p>80% of COVID-19 cases are generally mild and self-limiting, and may require no treatment. Lacking licensed drugs for SARS-CoV-2, therapeutic approaches in severely ill patients are limited to supportive care and empirical use of antibiotics to prevent or treat secondary infections [
 <xref rid="C84" ref-type="bibr">84</xref>, 
 <xref rid="C86" ref-type="bibr">86</xref>, 
 <xref rid="C161" ref-type="bibr">161</xref>]. To provide active treatment for SARS-CoV-2, drugs potentially inhibiting viral replication are of interest (
 <xref ref-type="fig" rid="F2">figure 2</xref>) [
 <xref rid="C162" ref-type="bibr">162</xref>].
</p>
